Latanoprost – a lasting glaucoma breakthrough

Latanoprost was a game-changing glaucoma therapy and still remains a go-to treatment for many ophthalmologists more than two decades later. PROFESSOR JOHN GRIGG – an investigator on an important clinical trial for the drug in 1996 – traces its history and explains how it fits into the treatment algorithm today.

Read more

Elective surgery post-COVID

An elective surgery shutdown as part of the COVID-19 response wreaked havoc on an already-stretched hospital system last year. Insight checks in on how each state is faring one year on. Read more

Streamlining the optometric Medicare schedule

With optometrists performing three-quarters of all eye exams in Australia, the optometric Medicare schedule has a major bearing on the quality of eye health in this country. Insight dives into the MBS Taskforce’s endorsed report that could reshape primary eyecare for decades to come.

Read more

Making the independent optometrist look good

Zacharia Naumann Optometry has made its frames range a defining feature of its practice. Practice manager BERNIE ZACHARIA explains how a 15-year partnership with Eyes Right Optical has helped the business flourish in the face of increasing competition.

Read more

How optometry is bouncing back

Specsavers data has quantified the impact of extended lockdowns on Victorian eye health for the first time. DR BEN ASHBY delves into the data, and explains why metropolitan Melbourne isn’t out of the woods yet.

Read more

Complexities and care for glaucoma suspects

The pathway for glaucoma suspects isn’t always clear cut with many maintaining this classification for prolonged periods. A major eyecare provider outlines its efforts to keep on top of this group, underpinned by a robust communications strategy.

Read more

Making a stand for MBGS under Medicare

Advances in glaucoma stent technology far outstripped the Medicare schedule early on, creating a disconnect that had far-reaching consequences. As Australia marks World Glaucoma Week this 7-13 March, Insight traces the turbulent MBGS journey that’s now considered an ophthalmology success story.

Read more